Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2014

Open Access 01-12-2014 | Review

Oligometastasis and oligo-recurrence: more than a mirage

Authors: Fang Huang, Gang Wu, Kunyu Yang

Published in: Radiation Oncology | Issue 1/2014

Login to get access

Abstract

The standard treatment choice for cancer metastasis has been systemic management, including cytotoxic chemotherapy, hormonal manipulation, and targeted therapy. Emerging evidence has shown an oligometastatic state, an intermediate state between limited primary cancer and polymetastatic cancer, in which local therapy for metastatic lesions results in satisfactory survival comparable to non-metastatic disease. We provide a comprehensive introduction of evidence from experimental and clinical studies in favor of the oligometastatic phenotype, we review the efficacy and safety of surgery and stereotactic body radiotherapy in the treatment of oligometastases, and finally, we discuss the way to differentiate the oligometastatic state from polymetastasis.
Literature
1.
Weichselbaum RR, Hellman S: Oligometastases revisited. Nat Rev Clin Oncol. 2011, 8: 378-382.PubMed
2.
Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol. 1995, 13: 8-10.PubMed
3.
4.
Niibe Y, Chang JY: Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med. 2012, 2012: 261096-10.1155/2012/261096.PubMedCentralCrossRefPubMed
5.
Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie R, Wigler M: Tumour evolution inferred by single-cell sequencing. Nature. 2011, 472: 90-94. 10.1038/nature09807.PubMedCentralCrossRefPubMed
6.
Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science (New York, NY). 1977, 197: 893-895. 10.1126/science.887927.CrossRef
7.
Shindo-Okada N, Takeuchi K, Nagamachi Y: Establishment of cell lines with high- and low-metastatic potential from PC-14 human lung adenocarcinoma. Jpn J Cancer Res. 2001, 92: 174-183. 10.1111/j.1349-7006.2001.tb01080.x.CrossRefPubMed
8.
Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 2001, 7: 630-636.PubMedCentralPubMed
9.
Chambers AF, Hill RP, Ling V: Tumor heterogeneity and stability of the metastatic phenotype of mouse KHT sarcoma cells. Cancer Res. 1981, 41: 1368-1372.PubMed
10.
Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010, 467: 1114-1117. 10.1038/nature09515.PubMedCentralCrossRefPubMed
11.
Wuttig D, Baier B, Fuessel S, Meinhardt M, Herr A, Hoefling C, Toma M, Grimm MO, Meye A, Rolle A, Wirth MP: Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer. 2009, 125: 474-482. 10.1002/ijc.24353.CrossRefPubMed
12.
Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007, 25: 4575-4580. 10.1200/JCO.2007.11.0833.CrossRefPubMed
13.
Bergenfeldt M, Jensen BV, Skjoldbye B, Nielsen D: Liver resection and local ablation of breast cancer liver metastases-a systematic review. Eur J Surg Oncol. 2011, 37: 549-557. 10.1016/j.ejso.2011.04.013.CrossRefPubMed
14.
Saxena A, Chua TC, Perera M, Chu F, Morris DL: Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012, 21: e131-141. 10.1016/j.suronc.2012.05.001.CrossRefPubMed
15.
Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, Couturier J, Levy-Gabriel C, Lumbroso-Le Rouic L, Desjardins L, Salmon RJ: Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol. 2009, 35: 1192-1197. 10.1016/j.ejso.2009.02.016.CrossRefPubMed
16.
Ercolani G, Grazi GL, Ravaioli M, Ramacciato G, Cescon M, Varotti G, Del Gaudio M, Vetrone G, Pinna AD: The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol. 2005, 12: 459-466. 10.1245/ASO.2005.06.034.CrossRefPubMed
17.
Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le Treut YP, Belghiti J, Mantion G, Mentha G: Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006, 244: 524-535. 10.1097/01.sla.0000246847.02058.1b.PubMedCentralCrossRefPubMed
18.
Reddy SK, Barbas AS, Marroquin CE, Morse MA, Kuo PC, Clary BM: Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg. 2007, 204: 372-382. 10.1016/j.jamcollsurg.2006.12.019.CrossRefPubMed
19.
Hoffmann K, Franz C, Hinz U, Schirmacher P, Herfarth C, Eichbaum M, Buchler MW, Schemmer P: Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010, 17: 1546-1554. 10.1245/s10434-010-0931-5.CrossRefPubMed
20.
Rehders A, Peiper M, Stoecklein NH, Alexander A, Boelke E, Knoefel WT, Rogiers X: Hepatic metastasectomy for soft-tissue sarcomas: is it justified?. World J Surg. 2009, 33: 111-117. 10.1007/s00268-008-9777-4.CrossRefPubMed
21.
Small R, Lubezky N, Ben-Haim M: Current controversies in the surgical management of colorectal cancer metastases to the liver. Isr Med Assoc J. 2007, 9: 742-747.PubMed
22.
Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995, 31: 1237-1248. 10.1016/0360-3016(94)00418-K.CrossRefPubMed
23.
Mendez Romero A, Hoyer M: Radiation therapy for liver metastases. Curr Opin Support Palliat Care. 2012, 6: 97-102. 10.1097/SPC.0b013e32834de6d8.CrossRefPubMed
24.
Wada H, Takai Y, Nemoto K, Yamada S: Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys. 2004, 58: 1114-1120. 10.1016/j.ijrobp.2003.08.012.CrossRefPubMed
25.
Sawrie SM, Fiveash JB, Caudell JJ: Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity. Cancer Control. 2010, 17: 111-119.PubMed
26.
Lanciano R, Lamond J, Yang J, Feng J, Arrigo S, Good M, Brady L: Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol. 2012, 2: 23-10.3389/fonc.2012.00023.PubMedCentralCrossRefPubMed
27.
Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P: Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007, 67: 793-798. 10.1016/j.ijrobp.2006.10.025.CrossRefPubMed
28.
Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Hoss A, Schlegel W, Wannenmacher MF: Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001, 19: 164-170.PubMed
29.
Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar LE: Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006, 45: 848-855. 10.1080/02841860600904870.CrossRefPubMed
30.
Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA: Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009, 27: 1585-1591. 10.1200/JCO.2008.20.0600.CrossRefPubMed
31.
Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC: Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol. 2006, 45: 831-837. 10.1080/02841860600897934.CrossRefPubMed
32.
Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, Schwarz RE, Weatherall P, Chinsoo Cho L: Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011, 18: 1081-1087. 10.1245/s10434-010-1405-5.CrossRefPubMed
33.
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009, 27: 1572-1578. 10.1200/JCO.2008.19.6329.CrossRefPubMed
34.
Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005, 62: 1371-1378. 10.1016/j.ijrobp.2005.01.002.CrossRefPubMed
35.
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases.J Thorac Cardiovasc Surg 1997, 113:37–49,
36.
Choong PF, Pritchard DJ, Rock MG, Sim FH, Frassica FJ: Survival after pulmonary metastasectomy in soft tissue sarcoma Prognostic factors in 214 patients. Acta Orthop Scand. 1995, 66: 561-568. 10.3109/17453679509002316.CrossRefPubMed
37.
Casiraghi M, De Pas T, Maisonneuve P, Brambilla D, Ciprandi B, Galetta D, Borri A, Gasparri R, Petrella F, Tessitore A, Guarize J, Donghi SM, Veronesi G, Solli P, Spaggiari L: A 10-year single-center experience on 708 lung metastasectomies: the evidence of the “international registry of lung metastases”. J Thorac Oncol. 2011, 6: 1373-1378. 10.1097/JTO.0b013e3182208e58.CrossRefPubMed
38.
Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H: Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 2002, 74: 1653-1657. 10.1016/S0003-4975(02)03803-1.CrossRefPubMed
39.
Kanemitsu Y, Kato T, Hirai T, Yasui K: Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004, 91: 112-120. 10.1002/bjs.4370.CrossRefPubMed
40.
Petersen RP, Hanish SI, Haney JC, Miller CC, Burfeind WR, Tyler DS, Seigler HF, Wolfe W, D’Amico TA, Harpole DH: Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007, 133: 104-110. 10.1016/j.jtcvs.2006.08.065.CrossRefPubMed
41.
Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, Sasaki M, Suzuki H, Takao H, Nakade M: Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg. 2002, 124: 1007-1013. 10.1067/mtc.2002.125165.CrossRefPubMed
42.
Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G: Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg. 2007, 84: 203-210. 10.1016/j.athoracsur.2007.03.028.CrossRefPubMed
43.
Meimarakis G, Angele M, Staehler M, Clevert DA, Crispin A, Ruttinger D, Lohe F, Preissler G, Hatz RA, Winter H: Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg. 2011, 202: 158-167. 10.1016/j.amjsurg.2010.06.029.CrossRefPubMed
44.
Liu D, Abolhoda A, Burt ME, Martini N, Bains MS, Downey RJ, Rusch VW, Bosl GJ, Ginsberg RJ: Pulmonary metastasectomy for testicular germ cell tumors: a 28-year experience. Ann Thorac Surg. 1998, 66: 1709-1714. 10.1016/S0003-4975(98)00940-0.CrossRefPubMed
45.
Suri RM, Deschamps C, Cassivi SD, Nichols FC, Allen MS, Schleck CD, Pairolero PC: Pulmonary resection for metastatic malignant fibrous histiocytoma: an analysis of prognostic factors. Ann Thorac Surg. 2005, 80: 1847-1852. 10.1016/j.athoracsur.2005.05.004.CrossRefPubMed
46.
Clavero JM, Deschamps C, Cassivi SD, Allen MS, Nichols FC, Barrette BA, Larson DR, Pairolero PC: Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg. 2006, 81: 2004-2007. 10.1016/j.athoracsur.2006.01.068.CrossRefPubMed
47.
Garcia Franco CE, Torre W, Tamura A, Guillen-Grima F, San-Julian M, Martin-Algarra S, Pardo FJ: Long-term results after resection for bone sarcoma pulmonary metastases. Eur J Cardiothorac Surg. 2010, 37: 1205-1208. 10.1016/j.ejcts.2009.11.026.CrossRefPubMed
48.
Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, Richter A, Wilbert J, Flentje M: Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2009, 74: 47-54. 10.1016/j.ijrobp.2008.06.1939.CrossRefPubMed
49.
Hamamoto Y, Kataoka M, Yamashita M, Nogami N, Sugawara Y, Kozuki T, Sawada S, Suehisa H, Shinohara S, Nakajima N, Shinkai T: Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors. Jpn J Radiol. 2012, 30: 430-434. 10.1007/s11604-012-0071-x.CrossRefPubMed
50.
Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, Mizowaki T, Yano S, Hiraoka M: Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008, 72: 398-403. 10.1016/j.ijrobp.2008.01.002.CrossRefPubMed
51.
Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros L, Schell MC: Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol. 2006, 45: 808-817. 10.1080/02841860600908954.CrossRefPubMed
52.
Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, Botticella A, Ciammella P, Iftode C, Buffoni L, Ruffinie E, Scagliottif GV: Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012, 75: 77-81. 10.1016/j.lungcan.2011.04.021.CrossRefPubMed
53.
Takahashi W, Yamashita H, Niibe Y, Shiraishi K, Hayakawa K, Nakagawa K: Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases. Pulmonary medicine. 2012, 2012: 454107-10.1155/2012/454107.PubMedCentralCrossRefPubMed
54.
Takahashi W, Nakajima M, Yamamoto N, Yamada S, Yamashita H, Nakagawa K, Tsuji H, Kamada T: Carbon ion radiotherapy for oligo-recurrent lung metastases from colorectal cancer: a feasibility study. Radiat Oncol. 2014, 9: 68-10.1186/1748-717X-9-68.PubMedCentralCrossRefPubMed
55.
Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE: Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009, 27: 1579-1584. 10.1200/JCO.2008.19.6386.CrossRefPubMed
56.
Hof H, Hoess A, Oetzel D, Debus J, Herfarth K: Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol. 2007, 183: 673-678. 10.1007/s00066-007-1724-z.CrossRefPubMed
57.
Fritz P, Kraus HJ, Muhlnickel W, Hammer U, Dolken W, Engel-Riedel W, Chemaissani A, Stoelben E: Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol. 2006, 1: 30-10.1186/1748-717X-1-30.PubMedCentralCrossRefPubMed
58.
Hamamoto Y, Kataoka M, Yamashita M, Shinkai T, Kubo Y, Sugawara Y, Inoue T, Sakai S, Aono S, Takahashi T, Semb T, Uwatsu K: Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: in comparison with primary lung cancer. Jpn J Clin Oncol. 2010, 40: 125-129. 10.1093/jjco/hyp129.CrossRefPubMed
59.
Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T: Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011, 101: 255-259. 10.1016/j.radonc.2011.05.033.CrossRefPubMed
60.
Baschnagel AM, Mangona VS, Robertson JM, Welsh RJ, Kestin LL, Grills IS: Lung metastases treated with image-guided stereotactic body radiation therapy. Clin Oncol. 2013, 25: 236-241. 10.1016/j.clon.2012.12.005.CrossRef
61.
Muth A, Persson F, Jansson S, Johanson V, Ahlman H, Wangberg B: Prognostic factors for survival after surgery for adrenal metastasis. Eur J Surg Oncol. 2010, 36: 699-704. 10.1016/j.ejso.2010.04.002.CrossRefPubMed
62.
Zheng QY, Zhang GH, Zhang Y, Guo YL: Adrenalectomy may increase survival of patients with adrenal metastases. Oncology letters. 2012, 3: 917-920.PubMedCentralPubMed
63.
Suzuki H: Laparoscopic adrenalectomy for adrenal carcinoma and metastases. Curr Opin Urol. 2006, 16: 47-53. 10.1097/01.mou.0000193378.14694.9b.CrossRefPubMed
64.
Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, Milano MT: Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009, 75: 71-75. 10.1016/j.ijrobp.2008.10.079.CrossRefPubMed
65.
Torok J, Wegner RE, Burton SA, Heron DE, Torok J, Wegner RE, Burton SA, Heron DE: Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol. 2011, 7: 145-151. 10.2217/fon.10.165.CrossRefPubMed
66.
Chamberlain MC: Spinal metastases from lung cancer-who benefits from decompression surgery?. Nat Clin Pract Neurol. 2007, 3: 188-189. 10.1038/ncpneuro0428.CrossRefPubMed
67.
Choi D, Morris S, Crockard A, Albert T, Bunger C, Fehlings M, Harrop J, Kawahara N, Martin JA, Massicotte EM, Mazel C, Oner FC, Peul W, Tomita K, Wang M: Assessment of quality of life after surgery for spinal metastases: position statement of the Global Spine Tumour Study Group. World Neurosurg. 2013, 80: e175-179. 10.1016/j.wneu.2013.02.054.CrossRefPubMed
68.
Lo SS, Sahgal A, Wang JZ, Mayr NA, Sloan A, Mendel E, Chang EL: Stereotactic body radiation therapy for spinal metastases. Discov Med. 2010, 9: 289-296.PubMed
69.
Lopes JC, Navarro A, Sole JM, Martinez M, Guedea F: Stereotactic body radiation therapy for spinal metastases. Clin Transl Oncol. 2010, 12: 639-642. 10.1007/s12094-010-0570-0.CrossRefPubMed
70.
Cunha MV, Al-Omair A, Atenafu EG, Masucci GL, Letourneau D, Korol R, Yu E, Howard P, Lochray F, da Costa LB, Fehlings MG, Sahgal A: Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys. 2012, 84: e343-349. 10.1016/j.ijrobp.2012.04.034.CrossRefPubMed
71.
Boehling NS, Grosshans DR, Allen PK, McAleer MF, Burton AW, Azeem S, Rhines LD, Chang EL: Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine. 2012, 16: 379-386. 10.3171/2011.11.SPINE116.CrossRefPubMed
72.
Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA: Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?. Radiother Oncol. 2013, 107: 409-413. 10.1016/j.radonc.2013.05.024.CrossRefPubMed
73.
de Vin T, Engels B, Gevaert T, Storme G, De Ridder M: Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014, 25: 467-471. 10.1093/annonc/mdt537.CrossRefPubMed
74.
Milano MT, Katz AW, Zhang H, Okunieff P: Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012, 83: 878-886. 10.1016/j.ijrobp.2011.08.036.CrossRefPubMed
75.
Goslin R, Steele G, Zamcheck N, Mayer R, MacIntyre J: Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum. 1982, 25: 749-754. 10.1007/BF02553304.CrossRefPubMed
76.
Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002, 235: 759-766. 10.1097/00000658-200206000-00002.PubMedCentralCrossRefPubMed
77.
Giuliante F, Ardito F, Vellone M, Ranucci G, Federico B, Giovannini I, Nuzzo G: Role of the surgeon as a variable in long-term survival after liver resection for colorectal metastases. J Surg Oncol. 2009, 100: 538-545. 10.1002/jso.21393.CrossRefPubMed
78.
Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M: Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006, 94: 982-999. 10.1038/sj.bjc.6603033.PubMedCentralCrossRefPubMed
79.
Suemitsu R, Takeo S, Kusumoto E, Hamatake M, Ikejiri K, Saitsu H: Results of a pulmonary metastasectomy in patients with colorectal cancer. Surg Today. 2011, 41: 54-59. 10.1007/s00595-009-4244-x.CrossRefPubMed
80.
Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, Nakagawa K, Fukuhara K, Maeda H, Takeda S, Minami M, Ohno Y, Matsuda H: Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg. 2004, 78: 238-244. 10.1016/j.athoracsur.2004.02.017.CrossRefPubMed
81.
Salah S, Watanabe K, Welter S, Park JS, Park JW, Zabaleta J, Ardissone F, Kim J, Riquet M, Nojiri K, Gisabella M, Kim SY, Tanaka K, Ali BA: Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model. Ann Oncol. 2012, 23: 2649-2655. 10.1093/annonc/mds100.CrossRefPubMed
82.
Meimarakis G, Ruttinger D, Stemmler J, Crispin A, Weidenhagen R, Angele M, Fertmann J, Hatz RA, Winter H: Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer. Ann Thorac Surg. 2013, 95: 1170-1180. 10.1016/j.athoracsur.2012.11.043.CrossRefPubMed
83.
Ashworth A, Rodrigues G, Boldt G, Palma D: Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013, 82: 197-203. 10.1016/j.lungcan.2013.07.026.CrossRefPubMed
84.
Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990, 322: 494-500. 10.1056/NEJM199002223220802.CrossRefPubMed
85.
Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004, 363: 1665-1672. 10.1016/S0140-6736(04)16250-8.CrossRefPubMed
86.
Spelt L, Andersson B, Nilsson J, Andersson R: Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review. Eur J Surg Oncol. 2012, 38: 16-24. 10.1016/j.ejso.2011.10.013.CrossRefPubMed
87.
Kanzaki R, Higashiyama M, Fujiwara A, Tokunaga T, Maeda J, Okami J, Nishimura K, Kodama K: Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardiothorac Surg. 2011, 39: 167-172. 10.1016/j.ejcts.2010.05.021.CrossRefPubMed
88.
Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG: Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008, 247: 125-135. 10.1097/SLA.0b013e31815aa2c2.CrossRefPubMed
89.
Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, Kulisch E, Saeger HD: Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int. 2009, 29: 89-102. 10.1111/j.1478-3231.2008.01845.x.CrossRefPubMed
90.
Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, Lodge JP, Toogood GJ: Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007, 246: 806-814. 10.1097/SLA.0b013e318142d964.CrossRefPubMed
91.
Minagawa M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, Makuuchi M: Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. Arch Surg. 2007, 142: 269-276. 10.1001/archsurg.142.3.269. discussion 277CrossRefPubMed
92.
Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich JL, Darga TE, Fan H, Karpenko O, Paty PB, Posner MC, Chmura SJ, Hellman S, Ferguson MK, Weichselbaum RR: Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012, 7: e50141-10.1371/journal.pone.0050141.PubMedCentralCrossRefPubMed
Metadata
Title
Oligometastasis and oligo-recurrence: more than a mirage
Authors
Fang Huang
Gang Wu
Kunyu Yang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-014-0230-6

Other articles of this Issue 1/2014

Radiation Oncology 1/2014 Go to the issue

Research

Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts

Research

Refractory trigeminal neuralgia treatment outcomes following CyberKnife radiosurgery

Research

Particle beam radiation therapy using carbon ions and protons for oligometastatic lung tumors

Research

Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy

Research

Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy

Research

Impact of body-mass factors on setup displacement in patients with head and neck cancer treated with radiotherapy using daily on-line image guidance